Edition:
United Kingdom

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.27USD
23 May 2018
Change (% chg)

$-0.01 (-4.51%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.27
Volume
119,417
Avg. Vol
167,336
52-wk High
$1.21
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytori Therapeutics Inc ::SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​.  Full Article

Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Cytori Therapeutics Inc :Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​.  Full Article

Cytori reports Q3 loss per share $0.14
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cytori Therapeutics Inc :Cytori reports third quarter 2017 business and financial results.Q3 loss per share $0.14.Cytori Therapeutics Inc - ‍received U.S. FDA IDE approval for relief, a thermal burn pilot trial related to ongoing barda contract​.Cytori Therapeutics Inc - ‍expects full year 2017 operating cash burn to be lower than 2016, primarily due to restructuring announced in September 2017​.  Full Article

Cytori Therapeutics Q2 loss per share $0.43
Thursday, 4 Aug 2016 

Cytori Therapeutics Inc : Cytori reports second quarter 2016 business and financial results . Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.43 . Reiterated financial guidance for 2016 .Says q2 total revenues of $2.8 million versus $5.8 million for same periods in 2015.  Full Article

Cytori completes enrollment in U.S. phase III scleroderma trial
Tuesday, 7 Jun 2016 

Cytori Therapeutics Inc :Cytori announces enrollment completion in U.S. Phase III scleroderma trial.  Full Article

BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin

* CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN